AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03234842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Concurrent weekly chemotherapy at standard doses
Study NCT01955720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655075
Study NCT00815542 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: double balloon catheter
Description: cervical ripening using double balloon catheter
Study NCT00815542 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: prostaglandins E2
Description: prostaglandins E2 - Intravaginal Propess for 24 hours
Study NCT00945724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, liposomal cytarabine, methotrexate
Description: Weeks 1-15:~* 6 cycles of CHOP on Days 1 to 5, to be repeated q21 Days~* Rituximab 375 mg/m2 on Day 0 or Day 1 of every CHOP cycle~* IT chemoth:Depocyte 50 mg on Day 0 of cycles 2,3,4\&5 of R-CHOP~Weeks 18-22:~• Methotrexate 1.5 g/m2 q14 Days x 2~From Week 24:~• Scrotal prophylactic radiotherapy or involved field radiotherapy(but can be planned concomitantly to R-CHOP in pts with bilateral disease)
Study NCT03887442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m2 may be infused, intravenously, every week.
Study NCT00395707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lucentis
Description: 0.3mg/0.05 ml or 0.5mg/0.05 ml
Study NCT01118208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blister packaging medications
Description: Dispensing prescription medications on pre-filled blister package cards.
Study NCT01118208 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dispense as usual
Description: Dispensing prescription medications in standard pill bottles.
Study NCT03690505 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Interviews
Description: informant-based questionnaire semi-structured individual interviews focus group interviews
Study NCT01990950 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zenith® Fenestrated AAA Endovascular Graft
Description: The Zenith® Fenestrated AAA Endovascular Graft with the H\&L-B One-Shot™ Introduction System is indicated for the endovascular treatment of patients with abdominal aortic or aortoiliac aneursyms having morphology suitable for endovascular repair
Study NCT02856464 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DLI will be administered to all patients at Month 4 (+/- 20 days) after stem cell transplant regardless of peripheral blood CD3 chimerism (including if they have full donor chimerism)
Study NCT02856464 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: DLI will be administered from Month 6 (+/- 20 days) after stem cell transplant according to institutional practice
Study NCT00205569 — intervention group
Intervention type: BEHAVIORAL
Intervention: First Steps Educational Curriculum
Description: 10 sessions with the research participant to review an educational curriculum regarding brain injury rehabilitation and community reintegration
Study NCT01681589 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulator (TDCS)
Description: Group will receive active TDCS
Study NCT01681589 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control Group
Description: This group will receive Sham TDCS
Study NCT01681589 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Healthy Control Group
Description: Healthy Controls will be involved in the Study. Healthy Controls will receive no Intervention. There will be 1 screening visit and 1 testing visits.
Study NCT02298192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/liraglutide
Description: For subcutaneous (s.c., under the skin) injection, once daily. Subjects will be instructed to continue with the same dose of OADs (metformin alone or in combination with pioglitazone), as prior to the trial.
Study NCT03887442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab + Paclitaxel
Description: Cetuximab 250 mg/m2 and Paclitaxel 80 mg/m2, both may be infused intravenously, every week. Cetuximab will be administered prior to paclitaxel.
Study NCT02647190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erwinia Chrysanthemi asparaginase
Study NCT00357799 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VeinViewer
Description: Using the VeinViewer, IV attempts will be made
Study NCT03773029 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: soy isoflavone
Description: 100 mg soy isoflavone (as 2 capsules)
Study NCT03773029 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 capsules of placebo
Study NCT03524040 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SEB-250
Description: Gold microparticles (SEB-250) are massaged into 2 or 3 2x2 cm facial areas and exposed to 2 pulses from a diode laser
Study NCT06447857 — intervention group
Intervention type: OTHER
Intervention: Cardiac MRI
Description: This retrospective study included patients diagnosed with STEMI at the Affiliated Hospital of Xuzhou Medical University. All patients underwent CMR.
Study NCT01692535 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intubation
Description: Intubation with one of the six videolaryngoscopes
Study NCT02948660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem Tartrate Tablets
Description: All participants were administered 10 mg of zolpidem tartrate tablets either via a feeding tube (for patients with prolonged disorders of consciousness) or orally.
Study NCT02732925 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arm 2 Balloon Kyphoplasty
Description: Arm 2 Balloon Kyphoplasty (Medtronic LCC) and Conservative Treatment~Subjects will be blinded and randomised to Arm 2 and will undergo a general anaesthetic and undergo a balloon kyphoplasty surgical procedure. They will also be treated with conservative management.~Below is a list of the conservative management they will be managed by their Doctor:~1. Bisphosphonates~2. Pain relief~3. Systemic chemotherapy for Myeloma disease~4. Bed rest~5. Radiotherapy~6. Physiotherapy
Study NCT02732925 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Conservative Management
Description: Patients recruited to Arm 1 and Arm 2 will undergo conservative management for Multiple Myeloma recommended by their Consultant Hematologist.~* Concomitant treatment with bisphosphonates~* Pain relief as required~* Systemic chemotherapy for Myeloma disease~* Bed rest~* Radiotherapy~* Physiotherapy
Study NCT02732925 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative Management
Description: Patients recruited to Arm 1 and Arm 2 will undergo conservative management for Multiple Myeloma recommended by their Consultant Hematologist.~* Concomitant treatment with bisphosphonates~* Pain relief as required~* Systemic chemotherapy for Myeloma disease~* Bed rest~* Radiotherapy~* Physiotherapy
Study NCT01554072 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Home based pulmonary rehabilitation with exercise
Description: After each group will receive the randomization their booklets containing the exercise routine that should be performed at home., to be held three times a week for two consecutive months. Is also scheduled a visit to the laboratory biweekly Respiratory Functional Assessment in which patients demonstrate their exercise routine program RP semi-home settings for any load, postural corrections and execution of physical exercise, should be refocused.
Study NCT01554072 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home based pulmonary rehabilitation with exercise
Description: After each group will receive the randomization their booklets containing the exercise routine that should be performed at home., to be held three times a week for two consecutive months. Is also scheduled a visit to the laboratory biweekly Respiratory Functional Assessment in which patients demonstrate their exercise routine program RP semi-home settings for any load, postural corrections and execution of physical exercise, should be refocused.
Study NCT02647398 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vigorous aerobic training
Description: Supervised vigorous aerobic training
Study NCT02647398 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Vigorous aerobic training
Description: Supervised vigorous aerobic training
Study NCT01839929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prograf
Description: oral
Study NCT01839929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advagraf
Description: oral
Study NCT00874861 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptide vaccine + Poly-ICLC
Description: Subcutaneously in right or left upper arms with intact draining axillary nodes. Each will be injected to the same location in the same arm as the previous vaccine was administered. In case of no intact axillary lymph nodes as draining nodes, vaccines will be administered in the upper thigh on the same side with intact inguinal lymph nodes.~Vaccine will be administered on weeks 0,3,6,9,12,15,18 and 21. Poly-ICLC First course(20 mg/kg i.m., up to 1640 µg/injection) will be administered on an outpatient basis in the Clinical \& Translational Research Center (CTRC)the day of the first GAA/TT-vaccine and on day 4 after the vaccine. For each of the repeated vaccinations (on Weeks 3,6,9,12,15,18 and 21) poly-ICLC will be administered on day of the vaccine and on day 4 after the vaccine.
Study NCT02835222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT02835222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Given IV
Study NCT02835222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV
Study NCT02835222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin Hydrochloride
Description: Given IV
Study NCT01706939 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Reduced Dose Radiation
Description: Reduced Dose Radiation (5600 cGy) dose radiotherapy
Study NCT01706939 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dose Radiation
Description: Standard Dose Radiation (7000 cGy) dose radiotherapy
Study NCT01706939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Day 1, every 7 days ( + 2 days)
Study NCT01706939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Day 1, every 7 days ( + 2 days)
Study NCT00395707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: 0.3mg/0.05 ml or 0.5mg/0.05 ml
Study NCT00395707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab (Lucentis)
Description: 0.3mg/0.05 ml intravitreally
Study NCT00395707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab (Lucentis)
Description: 0.5mg/0.05 ml
Study NCT00374543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Description: Ziprasidone, flexibly dosed from 40 to 160 mg/day, for 8 weeks.
Study NCT00374543 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered daily for 8 weeks
Study NCT01740856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rest three hours
Description: Intervention group (IG), will maintain bed rest supine for two hours after the digital compression. After this period prescribed, patients sit in bed with the head elevated at 45 degrees for 50 minutes and then walk within the unit hemodynamic for about 10 minutes. Afterwards patients remain sitting out of bed in hemodynamics unit, until they are five hours, then they will be discharge.
Study NCT02835222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Given PO
Study NCT00045110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: given orally
Study NCT00045110 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: correlative studies
Study NCT00045110 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: correlative studies
Study NCT01923155 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy
Study NCT02283931 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TTE / NICOM
Study NCT03411967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: apatinib mesylate tablets 500mg, po, qd, continued until the next cycle, taking on an empty stomach (daily taken at the same time), every 3 weeks For one cycle, a total of 4 to 6 cycles of treatment, apatinib has been taken until the disease progresses, intolerable toxicity.
Study NCT03411967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel, 60 mg / m2, d1, iv ,every 3 weeks For one cycle, a total of 4 to 6 cycles of treatment
Study NCT01740856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rest five hours
Description: Control group (CG) maintain bed rest supine for four hours after the digital compression. After this period, the patients sit in bed with the head elevated at 45 degrees for 50 minutes and then walk into the unit hemodynamic for 10 minutes. After that patients receive discharge.
Study NCT03682718 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcervical Foley catheter
Description: combined methods of induction of labor Floey Catheter with misoprstol
Study NCT03682718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Misoprstol inserted vaginally for induction of labor
Study NCT03682718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Misoprstol inserted vaginally for induction of labor
Study NCT00126438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 123I-mIBG (meta-iodobenzylguanidine)
Description: Single Dose
Study NCT03093545 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Equine Rabies Immunoglobulin
Description: 40 IU per kg of body weight of ERIG at Day 0
Study NCT02575885 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Cigarette
Description: Receive different type of ENDS product at each visit
Study NCT02575885 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Cigarette
Description: Receive BLU e-cigarette ENDS product
Study NCT03093545 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Equine Rabies Immunoglobulin
Description: 40 IU per kg of body weight of ERIG at Day 0
Study NCT03093545 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Purified chick-embryo cell rabies vaccine
Description: 1 ml of PCEC Rabies vaccine on days 0, 3, 7, 14 and 28.
Study NCT03093545 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Purified chick-embryo cell rabies vaccine
Description: 1 ml of PCEC Rabies vaccine on days 0, 3, 7, 14 and 28.
Study NCT03453359 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIS monitor
Description: The investigators will place on the forehead of all patients the sensor BIS quatroTM, that connects with this monitor, and they will guide sedation and will record the values obtained.
Study NCT03453359 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ramsay scale
Description: In this group, sedation is guided by the Ramsay monitoring scale. The investigators will talk with the patients and will determine the corresponding level of sedation.
Study NCT02660385 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: This behavioral intervention includes strategies for modifying thoughts, cognitions and behaviors regarding sleep provided by a therapist in a group format.
Study NCT02660385 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Management Education for Heart Failure
Description: This is an educational education designed to teach patients about self-management their heart failure. It includes information on medications, lifestyle, cardiac devices, diet, and when to seek assistance from a health care provider.
Study NCT01173159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omegaven
Description: For the first two days of treatment, subjects will receive Omegaven® at 0.5 g/kg per day to assess tolerance and will progress to a maintenance dosage of up to 1g/kg per day over 12 hours at an infusion rate of 1 g/kg/12 hours (10 ml/kg/12 hours). Dosing is based on previously described dosing of fish-oil emulsions as monotherapy noted within the literature. Omegaven® will be infused intravenously through either a central or peripheral catheter in conjunction with other parenteral nutrition containing dextrose and amino acids. Omegaven® is isotonic. It is compatible with parenteral nutrition solutions and may be co-infused via y-site.
Study NCT01280799 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance-based separated family treatment
Description: Family treatment that combines Acceptance and Commitment Therapy (ACT) for the adolescent with Parent Skills Training for caregivers. The treatment package is designed to increase willingness to experience difficult thoughts, feelings, and bodily sensations in order to engage in effective behavior. To facilitate this, caregivers are provided with psychoeducation on eating disorders and skills in behavior management, self-regulation, and emotion regulation.
Study NCT01199432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU（intravenous infusion）+epirubicin+cyclophosphamide
Description: 5-FU 200mg/m2 per day from day 1 to day 28 （Continuous intravenous infusion）; epirubicin 65mg/m2 per day on day 1 and day 8 and cyclophosphamide 500mg/m2 per day on day 1 and day 8 ; every 28 days as a cycle. Total four cycles is needed
Study NCT01199432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU（intravenous bolus）+epirubicin+cyclophosphamide
Description: 5-FU 500mg/m2 per day on day 1 and day 8（intravenous bolus）; epirubicin 65mg /m2 per day on day 1 and day 8 and cyclophosphamide 500mg/m2 per day on day 1 and day 8 ; every 28 days as a cycle. Total four cycles is needed.
Study NCT01199432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epirubicin+cyclophosphamide
Description: epirubicin 65mg/m2 per day on day 1 and day 8 and cyclophosphamide 500mg/m2 per day on day 1 and day 8 ; every 28 days as a cycle. Total four cycles is needed.
Study NCT02558426 — intervention group
Intervention type: PROCEDURE
Intervention: Venous Surgery
Description: Patients with Varicose Veins will undergo to venous surgery procedure. Samples obtained from patients undergoing surgical removal of varicose veins will be collected and immediately preserved at -80°. Briefly, the venous tissueswill be excised, homogenized with a motor-driven homogenizer and total RNA will be isolated using the Trizol reagent (Invitrogen, Milan, Italy), according to the manufacturer's instructions. The expression of ERα, ERβ and GPER will be quantified by real-time PCR using the Step OneTM sequence detection system (Applied Biosystems Inc., Milan, Italy), following the manufacturer's instructions
Study NCT01179633 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OPLON active patch
Study NCT01179633 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham patch
Study NCT01252433 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy density feeding study
Description: In a crossover study, children are served all foods 1 day a week for 3 weeks. Meal entrees will vary in energy density (100%, 85%, 75%).
Study NCT00578019 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IM Nailing
Description: Patients randomized to Arm 1, A will be treated with a retrograde intramedullary nailing of the femur fracture utilizing the Smith \& Nephew supracondylar nail.
Study NCT00578019 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LISS
Description: Group B patients will have their fracture stabilized with the LISS plates (Synthes \[USA\], Paoli, PA, USA).
Study NCT03085966 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous immune cell therapy
Description: Luteinizing Hormone Releasing Hormone Agonists (LHRH-a) and Autologous dendritic cells (DC) and central memory T cells (Tcm cells)
Study NCT00857090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMS201
Description: Stage 1: OMS201 irrigation solution at 3X the base concentration during surgery~Stage 2: OMS201 irrigation solution up to 10X the base concentration during surgery
Study NCT00857090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Stages 1-2: Vehicle irrigation solution during surgery
Study NCT01483027 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TheraSphere
Description: yttrium 90 microspheres
Study NCT00636246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sertraline/[S,S]-reboxetine
Description: Tablets, 50mg sertraline/2mg \[S,S\]-reboxetine for 3 days orally, followed by 100mg sertraline/4mg \[S,S\]-reboxetine for 4 and one half weeks, followed by 150mg sertraline/4mg \[S,S\]-reboxetine for 5 and one half weeks.
Study NCT00636246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sertraline/[S,S]-reboxetine
Description: Tablets, 50mg sertraline/2mg \[S,S\]-reboxetine for 3 days orally, followed by 100mg sertraline/4mg \[S,S\]-reboxetine for 4 and one half weeks, followed by 150mg sertraline/6mg \[S,S\]-reboxetine for 5 and one half weeks.